SCHEMBL969806

SCHEMBL969806

CC(C)OC(=O)NC1CCCNC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
OPRK1 P41145 1/20 0.47
CPN1 P15169 1/20 0.40
CPB2 Q96IY4 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
CYP2D6 P10635 1/20 0.40
TOP2A P11388 1/20 0.39
HSD11B1 P28845 1/20 0.39
PBK Q96KB5 2/20 0.37
SLC6A1 P30531 2/20 0.37
SLC6A11 P48066 1/20 0.37
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SLC6A13 Q9NSD5 1/20 0.37
PARP1 P09874 1/20 0.37
CHRNA1 P02708 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14486852 0.90 EPHX1 (0.41) MAPK1OPRK1HSD11B1PBKPARP1
SCHEMBL10060054 0.90 EPHX1 (0.41) MAPK1OPRK1HSD11B1PBKPARP1
Hydrochloric Acid SCHEMBL17560372 0.89 EPHX1 (0.40) MAPK1OPRK1TOP2AHSD11B1PARP1
Hydrochloric Acid SCHEMBL17560375 0.89 EPHX1 (0.40) MAPK1OPRK1TOP2AHSD11B1PARP1
SCHEMBL968984 0.85 MAPK1 (0.43) MAPK1OPRK1CPN1CPB2KDM4E
SCHEMBL27802917 0.84 CPN1 (0.41) MAPK1OPRK1CPN1CPB2KDM4E
SCHEMBL965984 0.83 MAPK1 (0.55) MAPK1OPRK1CPN1CPB2KDM4E
SCHEMBL27714012 0.83 MAPK1 (0.55) MAPK1OPRK1CPN1CPB2KDM4E
SCHEMBL12206726 0.83 HSD11B1 (0.40) KDM4ECYP2D6HSD11B1TSHRLMNA
Hydrochloric Acid SCHEMBL17560419 0.81 MAPK1 (0.54) MAPK1OPRK1KDM4EMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471775-B1 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor SUMITOMO CHEMICAL CO (JP) 2013-01-23 EP disclosed
EP-2471775-A1 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor SUMITOMO CHEMICAL CO., LTD. (JP) 2012-07-04 EP disclosed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 EP disclosed
US-20100331546-A1 METHOD FOR OPTICAL RESOLUTION OF ALKYL PIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-12-30 US disclosed
EP-2248803-A1 METHOD FOR OPTICAL RESOLUTION OF ALKYLPIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR Sumitomo Chemical Company, Limited (JP) 2010-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L MAPK1 3124/4885OPRK1 3123/4885CPN1 4364/4885
US-20100331546-A1 METHOD FOR OPTICAL RESOLUTION OF ALKYL PIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR FAR1, NOTUM, CYP51A1 MAPK1 3808/4885OPRK1 3206/4885CPN1 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.